Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT.

Ritari J, Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Salmenniemi U, Putkonen M, Volin L, Kwan T, Pastinen T, Itälä-Remes M, Partanen J.

Front Immunol. 2019 Jul 16;10:1625. doi: 10.3389/fimmu.2019.01625. eCollection 2019.

2.

Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, Tabrizi R, Sengeloev H, Ganser A, Cornelissen JJ, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Jul 2. pii: S1083-8791(19)30415-X. doi: 10.1016/j.bbmt.2019.06.031. [Epub ahead of print]

PMID:
31271887
3.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.

Poiré X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, Michallet M, Blaise D, Yakoub-Agha I, Maertens J, Richard Espiga C, Cornelissen J, Finke J, Mohty M, Esteve J, Nagler A; Acute Leukemia Working Party of the EBMT.

Haematologica. 2019 May 2. pii: haematol.2019.216168. doi: 10.3324/haematol.2019.216168. [Epub ahead of print]

4.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J.

Ann Hematol. 2019 Jul;98(7):1755-1763. doi: 10.1007/s00277-019-03669-z. Epub 2019 Apr 16.

PMID:
30993417
5.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

6.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P.

Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21.

PMID:
30664723
7.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.

Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.

8.

Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.

Poiré X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A, Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Mohty M, Esteve J, Nagler A.

Am J Hematol. 2019 Feb;94(2):231-239. doi: 10.1002/ajh.25355. Epub 2018 Dec 10.

PMID:
30456896
9.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.

Biol Blood Marrow Transplant. 2019 Mar;25(3):522-528. doi: 10.1016/j.bbmt.2018.10.017. Epub 2018 Nov 5.

PMID:
30408564
10.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A.

J Intern Med. 2019 Apr;285(4):407-418. doi: 10.1111/joim.12854. Epub 2018 Nov 16.

PMID:
30372796
11.

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.

Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA.

J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.

12.

Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up.

Martelin E, Volin L, Itälä-Remes M, Niittyvuopio R, Lindström V, Heiskanen J, Ruutu T, Nihtinen A.

Bone Marrow Transplant. 2019 Feb;54(2):334-337. doi: 10.1038/s41409-018-0290-6. Epub 2018 Aug 13. No abstract available.

PMID:
30104720
13.

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.

Ritari J, Hyvärinen K, Koskela S, Itälä-Remes M, Niittyvuopio R, Nihtinen A, Salmenniemi U, Putkonen M, Volin L, Kwan T, Pastinen T, Partanen J.

Leukemia. 2019 Jan;33(1):240-248. doi: 10.1038/s41375-018-0229-3. Epub 2018 Aug 8.

14.

Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussière-Wallet H, Bittenbring J, Shouval R, Savani B, Mohty M, Nagler A.

Bone Marrow Transplant. 2019 Apr;54(4):531-539. doi: 10.1038/s41409-018-0288-0. Epub 2018 Aug 7.

PMID:
30087463
15.

Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.

Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3.

16.

Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.

17.

Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience.

Niittyvuopio R, Juvonen E, Heiskanen J, Lindström V, Nihtinen A, Sahlstedt L, Volin L.

Transfusion. 2018 Aug;58(8):1973-1979. doi: 10.1111/trf.14649. Epub 2018 Apr 29.

PMID:
29707788
18.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.

Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen JJ, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Jun;53(6):683-691. doi: 10.1038/s41409-018-0165-x. Epub 2018 Apr 18.

PMID:
29670208
19.

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.

Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socié G, Tabrizi R, Cornelissen JJ, Ghavamzadeh A, Huynh A, Wu D, Yakoub-Agha I, Maertens J, Chevallier P, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Oct;53(10):1295-1303. doi: 10.1038/s41409-018-0169-6. Epub 2018 Apr 16.

PMID:
29662244
20.

Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, Itälä-Remes M, Wu D, Mohty M, Nagler A.

Cancer. 2018 Jun 15;124(12):2523-2533. doi: 10.1002/cncr.31354. Epub 2018 Mar 30.

21.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):778-785. doi: 10.1002/ajh.25091. Epub 2018 Mar 30.

22.

Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.

Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A.

Cancer. 2018 May 15;124(10):2134-2141. doi: 10.1002/cncr.31311. Epub 2018 Feb 22.

23.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A.

Blood Adv. 2017 Feb 28;1(7):477-485. doi: 10.1182/bloodadvances.2016002386. eCollection 2017 Feb 28.

24.

Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Przybyla B, Pinomäki A, Petäjä J, Joutsi-Korhonen L, Strandberg K, Hillarp A, Öhlin AK, Ruutu T, Volin L, Lassila R.

PLoS One. 2017 Dec 22;12(12):e0190007. doi: 10.1371/journal.pone.0190007. eCollection 2017.

25.

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Poiré X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socié G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A.

Haematologica. 2018 Feb;103(2):256-265. doi: 10.3324/haematol.2017.178251. Epub 2017 Dec 14.

26.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

27.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

28.

Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease.

Hyvärinen K, Ritari J, Koskela S, Niittyvuopio R, Nihtinen A, Volin L, Gallardo D, Partanen J.

Sci Rep. 2017 Nov 15;7(1):15666. doi: 10.1038/s41598-017-15915-3.

29.

A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.

Ruutu T, Nihtinen A, Niittyvuopio R, Juvonen E, Volin L.

Cancer. 2018 Feb 15;124(4):727-733. doi: 10.1002/cncr.31100. Epub 2017 Nov 7.

30.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

31.

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A.

J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695. Epub 2017 Nov 3.

PMID:
29027756
32.

Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.

Gorin NC, Labopin M, Pabst T, Remenyi P, Wu D, Huynh A, Volin L, Cahn JY, Yakoub-Agha I, Mercier M, Houhou M, Mohty M, Nagler A; Acute Leukemia Working Party of the EBMT.

Am J Hematol. 2017 Dec;92(12):1318-1323. doi: 10.1002/ajh.24904. Epub 2017 Sep 28.

33.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.

34.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86.

PMID:
28677682
35.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).

Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, Kröger N; CLL subcommittee, Chronic Malignancies Working Party.

Br J Haematol. 2017 Aug;178(4):521-533. doi: 10.1111/bjh.14791. Epub 2017 Jun 7.

PMID:
28589551
36.

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.

Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G.

Lancet Haematol. 2017 Jun;4(6):e293-e301. doi: 10.1016/S2352-3026(17)30081-9.

PMID:
28583289
37.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T.

J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2.

38.

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.

Canaani J, Savani BN, Labopin M, Michallet M, Craddock C, Socié G, Volin L, Maertens JA, Crawley C, Blaise D, Ljungman PT, Cornelissen J, Russell N, Baron F, Gorin N, Esteve J, Ciceri F, Schmid C, Giebel S, Mohty M, Nagler A.

Am J Hematol. 2017 Aug;92(8):789-796. doi: 10.1002/ajh.24771. Epub 2017 Jun 9.

39.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N.

Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. No abstract available.

40.

More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party.

Simonin M, Dalissier A, Labopin M, Willasch A, Zecca M, Mouhab A, Chybicka A, Balduzzi A, Volin L, Peters C, Bader P, Dalle JH.

Bone Marrow Transplant. 2017 Jul;52(7):1071-1073. doi: 10.1038/bmt.2017.66. Epub 2017 Apr 10. No abstract available.

PMID:
28394370
41.

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foá R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN.

Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.

42.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N.

Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.

PMID:
28319072
43.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.

Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, Kröger N.

Bone Marrow Transplant. 2017 Apr;52(4):552-560. doi: 10.1038/bmt.2016.329. Epub 2017 Jan 23.

PMID:
28112746
44.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

45.

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.

Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Apr;92(4):344-350. doi: 10.1002/ajh.24640. Epub 2017 Feb 7.

46.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. doi: 10.1038/bmt.2016.282. Epub 2016 Dec 12.

PMID:
27941763
47.

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.

J Hematol Oncol. 2016 Nov 8;9(1):118.

48.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Feb;52(2):209-215. doi: 10.1038/bmt.2016.266. Epub 2016 Nov 7. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.

PMID:
27819688
49.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.

Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T.

Ann Hematol. 2016 Dec;95(12):1971-1978. Epub 2016 Sep 20.

50.

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, Kyrcz-Krzemien S, Yakoub-Agha I, Aljurf M, Wu D, Michallet M, Arnold R, Mohty M, Nagler A.

Haematologica. 2017 Jan;102(1):139-149. doi: 10.3324/haematol.2016.145631. Epub 2016 Sep 29.

Supplemental Content

Support Center